Ensysce Biosciences Valuation
| ENSC Stock | USD 0.41 0.03 6.82% |
Ensysce Biosciences is undervalued. Ensysce Biosciences shows a prevailing Real Value of $4.4 per share. The current price of the firm is $0.41. Our model computes the value of Ensysce Biosciences from reviewing the firm fundamentals such as Profit Margin of (2.44) %, shares outstanding of 3.63 M, and Current Valuation of 922.92 K as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Ensysce Biosciences' valuation include:
Price Book 1.8434 | Enterprise Value | Enterprise Value Ebitda (0.50) | Price Sales 0.3568 | Forward PE 0.9496 |
Undervalued
Today
Please note that Ensysce Biosciences' price fluctuation is very risky at this time. Calculation of the real value of Ensysce Biosciences is based on 3 months time horizon. Increasing Ensysce Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Ensysce Biosciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Ensysce Stock. However, Ensysce Biosciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.41 | Real 4.4 | Target 16.45 | Hype 0.47 |
The real value of Ensysce Stock, also known as its intrinsic value, is the underlying worth of Ensysce Biosciences Company, which is reflected in its stock price. It is based on Ensysce Biosciences' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Ensysce Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Ensysce Biosciences helps investors to forecast how Ensysce stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Ensysce Biosciences more accurately as focusing exclusively on Ensysce Biosciences' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Ensysce Biosciences' intrinsic value based on its ongoing forecasts of Ensysce Biosciences' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Ensysce Biosciences' closest peers. If more than one evaluation category is relevant for Ensysce Biosciences we suggest using both methods to arrive at a better estimate.
Ensysce Biosciences Cash |
|
Ensysce Biosciences Total Value Analysis
Ensysce Biosciences is currently projected to have valuation of 922.92 K with market capitalization of 1.6 M, debt of 301.66 K, and cash on hands of 3.15 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Ensysce Biosciences fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
922.92 K | 1.6 M | 301.66 K | 3.15 M |
Ensysce Biosciences Investor Information
The company has price-to-book (P/B) ratio of 1.84. Some equities with similar Price to Book (P/B) outperform the market in the long run. Ensysce Biosciences recorded a loss per share of 6.35. The entity had not issued any dividends in recent years. The firm had 1:15 split on the 6th of December 2024. Based on the key indicators related to Ensysce Biosciences' liquidity, profitability, solvency, and operating efficiency, Ensysce Biosciences is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Ensysce Biosciences Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Ensysce Biosciences has an asset utilization ratio of 93.08 percent. This indicates that the Company is making $0.93 for each dollar of assets. An increasing asset utilization means that Ensysce Biosciences is more efficient with each dollar of assets it utilizes for everyday operations.Ensysce Biosciences Profitability Analysis
Based on Ensysce Biosciences' profitability indicators, Ensysce Biosciences may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Ensysce Biosciences' ability to earn profits and add value for shareholders.Net Loss | First Reported 2017-12-31 | Previous Quarter -1.7 M | Current Value -3.7 M | Quarterly Volatility 4 M |
For Ensysce Biosciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Ensysce Biosciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Ensysce Biosciences utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Ensysce Biosciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Ensysce Biosciences over time as well as its relative position and ranking within its peers.
Ensysce Biosciences Earnings per Share Projection vs Actual
By analyzing Ensysce Biosciences' earnings estimates, investors can diagnose different trends across Ensysce Biosciences' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Ensysce Biosciences is based on EPS before non-recurring items and includes expenses related to employee stock options.Ensysce Biosciences Ownership Allocation
Roughly 88.37 percent of Ensysce Biosciences outstanding shares are held by general public with 0.29 (percent) owned by insiders and only 11.34 % by other corporate entities.Ensysce Biosciences Profitability Analysis
The company reported the previous year's revenue of 5.21 M. Net Loss for the year was (7.99 M) with loss before overhead, payroll, taxes, and interest of (6.08 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Ensysce Biosciences' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Ensysce Biosciences and how it compares across the competition.
About Ensysce Biosciences Valuation
The stock valuation mechanism determines Ensysce Biosciences' current worth on a weekly basis. Our valuation model uses a comparative analysis of Ensysce Biosciences. We calculate exposure to Ensysce Biosciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Ensysce Biosciences's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -1.8 M | -1.9 M | |
| Pretax Profit Margin | (1.38) | (1.45) | |
| Operating Profit Margin | (1.16) | (1.22) | |
| Net Loss | (1.38) | (1.45) | |
| Gross Profit Margin | (0.44) | (0.47) |
Ensysce Biosciences Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 1.7 M | |
| Forward Price Earnings | 0.9496 |
Ensysce Biosciences Current Valuation Indicators
Valuation refers to the process of determining the present value of Ensysce Biosciences and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Ensysce we look at many different elements of the entity such as Ensysce's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Ensysce Biosciences, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Ensysce Biosciences' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Ensysce Biosciences' worth.Complementary Tools for Ensysce Stock analysis
When running Ensysce Biosciences' price analysis, check to measure Ensysce Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ensysce Biosciences is operating at the current time. Most of Ensysce Biosciences' value examination focuses on studying past and present price action to predict the probability of Ensysce Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ensysce Biosciences' price. Additionally, you may evaluate how the addition of Ensysce Biosciences to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |